Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19

Proceedings of the National Academy of Sciences of the United States of America
Raphaël CauchoisGilles Kaplanski

Abstract

Around the tenth day after diagnosis, ∼20% of patients with coronavirus disease 2019 (COVID-19)-associated pneumonia evolve toward severe oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with systemic inflammation often termed a "cytokine storm." Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra. We retrospectively compared 22 patients from three different centers in France with stages 2b and 3 COVID-19-associated pneumonia presenting with acute severe respiratory failure and systemic inflammation who received either standard-of-care treatment alone (10 patients) or combined with intravenous anakinra (12 patients). Treatment started at 300 mg⋅d-1 for 5 d, then tapered with lower dosing over 3 d. Both populations were comparable for age, comorbidities, clinical stage, and elevated biomarkers of systemic inflammation. All of the patients treated with anakinra improved clinically (P < 0.01), with no deaths, significant decreases in oxygen requirements (P < 0.05), and more days without invasive mechanical ventilation (P < 0.06), compared with the control...Continue Reading

References

Mar 25, 2016·Nature Reviews. Rheumatology·Alexei A GromFabrizio De Benedetti
Dec 16, 2016·PLoS Pathogens·Jeroen SlaatsMihai G Netea
Dec 17, 2017·Immunological Reviews·Gilles Kaplanski
Nov 22, 2018·Frontiers in Pharmacology·Giulio Cavalli, Charles A Dinarello
Sep 14, 2019·Nature Reviews. Rheumatology·Charles Anthony Dinarello
Mar 29, 2020·The Journal of Clinical Investigation·Guang ChenQin Ning
Apr 8, 2020·Journal of Medical Virology·Pan LuoJuan Li
May 5, 2020·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hasan K Siddiqi, Mandeep R Mehra

❮ Previous
Next ❯

Citations

Aug 23, 2020·International Journal of Molecular Sciences·Grégorie LebeauPhilippe Gasque
Oct 20, 2020·Frontiers in Cellular and Infection Microbiology·Anna Cláudia Calvielli Castelo BrancoRicardo Wesley Alberca
Oct 21, 2020·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Stefano ToldoAntonio Abbate
Oct 21, 2020·Molecular Neurobiology·Mohammad Azizur RahmanMd Alamin
Dec 17, 2020·Autoimmunity Reviews·Gilles KaplanskiLaurent Papazian
Oct 20, 2020·Chest·Sonali NarainUNKNOWN Northwell COVID-19 Research Consortium
Jan 2, 2021·Frontiers in Immunology·Julien CarvelliGilles Kaplanski
Jan 26, 2021·Journal of Developmental Origins of Health and Disease·Michael D WieseJanna L Morrison
Oct 29, 2020·Current Transplantation Reports·Mario Fernández-Ruiz, José María Aguado
Nov 17, 2020·Frontiers in Immunology·Taylon Felipe SilvaMilena Menegazzo Miranda-Sapla
Dec 29, 2020·Expert Review of Clinical Immunology·Philippe GautretDidier Raoult
Feb 15, 2021·European Journal of Internal Medicine·Laura PasinGiacomo Monti
Feb 2, 2021·Nano Today·Srinivasa Reddy BonamJagadeesh Bayry
Jan 13, 2021·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Joseph BalnisAriel Jaitovich
Mar 3, 2021·Cell Death Discovery·André C FerreiraThiago Moreno L Souza
Mar 7, 2021·Brain Sciences·Marcello CiaccioLuisa Agnello
Mar 13, 2021·Frontiers in Pediatrics·Sara Della PaoleraAndrea Taddio
Mar 16, 2021·Expert Opinion on Investigational Drugs·Binh T NgoIvan Fn Hung
Mar 20, 2021·Expert Review of Anti-infective Therapy·Anindita BanerjeeSasanka Chakrabarti
Mar 31, 2021·The Lancet Rheumatology·Juan SalvatierraJosé Hernández-Quero
Mar 9, 2021·ELife·Evdoxia KyriazopoulouEvangelos J Giamarellos-Bourboulis
Apr 6, 2021·The Lancet Rheumatology·Christoffer B NissenKaren Schreiber
May 1, 2021·Pharmaceutics·Matteo PuccettiStefano Giovagnoli
Dec 29, 2020·ACS Biomaterials Science & Engineering·Bader M JaraiCatherine A Fromen
May 14, 2021·Clinical Microbiology Reviews·Santhamani Ramasamy, Selvakumar Subbian
May 19, 2021·Nature Reviews. Immunology·Emma C MorrisMichel Sadelain
May 26, 2021·Current Opinion in Microbiology·Intan Mw DewiFrank L van de Veerdonk
Jun 1, 2021·Frontiers in Immunology·Xiaofang WangYuejin Liang
Jul 9, 2021·Therapeutics and Clinical Risk Management·Hong Peng LiQing Yun Li
Jul 4, 2021·Infection & chemotherapy·Manoj Kumar Reddy SomaguttaMarcos A Sanchez-Gonzalez
Jun 24, 2021·FEMS Microbiology Reviews·Milankumar PatelHoward E Gendelman
Jul 9, 2021·Signal Transduction and Targeted Therapy·Lan YangYufeng Zhou
Aug 11, 2021·Nature Reviews. Immunology·Setu M VoraHao Wu
Aug 10, 2021·International Immunopharmacology·Cassiano Martin Batista, Leonardo Foti

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Clinical Trials Mentioned

NCT04366232

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Giovanni FilocamoAlessandra Bandera
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Marco FranzettiStefania Piconi
The Lancet Rheumatology
Omar MaoujoudNadir Zemraoui
The Lancet Rheumatology
Xavier Valette, Damien du Cheyron
The Lancet Rheumatology
Nicolas Martin-SilvaAchille Aouba
© 2021 Meta ULC. All rights reserved